Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma
出版年份 2016 全文链接
标题
Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma
作者
关键词
-
出版物
CANCER
Volume 123, Issue 7, Pages 1212-1218
出版商
Wiley
发表日期
2016-11-29
DOI
10.1002/cncr.30458
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
- (2016) T. Tandstad et al. ANNALS OF ONCOLOGY
- Canadian consensus guidelines for the management of testicular germ cell cancer
- (2016) Lori Wood et al. CUAJ-Canadian Urological Association Journal
- Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience
- (2015) C. Chau et al. ANNALS OF ONCOLOGY
- 2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma
- (2015) S. Fischer et al. EUROPEAN JOURNAL OF CANCER
- Guidelines on Testicular Cancer: 2015 Update
- (2015) Peter Albers et al. EUROPEAN UROLOGY
- Germ Cell Cancer and Multiple Relapses: Toxicity and Survival
- (2015) Jakob Lauritsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance
- (2015) Christian Kollmannsberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Testicular Cancer, Version 2.2015
- (2015) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Increased stomach cancer risk following radiotherapy for testicular cancer
- (2014) M Hauptmann et al. BRITISH JOURNAL OF CANCER
- A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program
- (2014) Mette Saksø Mortensen et al. EUROPEAN UROLOGY
- Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience
- (2014) G. Cohn-Cedermark et al. Andrology
- Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance
- (2014) Peter Chung et al. Cancer Medicine
- Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. Oldenburg et al. ANNALS OF ONCOLOGY
- Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy
- (2013) Eric Leung et al. BJU INTERNATIONAL
- Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma
- (2013) A Horwich et al. BRITISH JOURNAL OF CANCER
- Long-term outcomes of radiotherapy for stage II testicular seminoma–the Mayo Clinic experience
- (2012) Christopher L. Hallemeier et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
- (2011) Jorge Aparicio et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group
- (2011) Torgrim Tandstad et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)
- (2011) R. Timothy D. Oliver et al. JOURNAL OF CLINICAL ONCOLOGY
- The Danish Pathology Register
- (2011) Beth Bjerregaard et al. SCANDINAVIAN JOURNAL OF PUBLIC HEALTH
- The Danish National Patient Register
- (2011) Elsebeth Lynge et al. SCANDINAVIAN JOURNAL OF PUBLIC HEALTH
- The Danish Register of Causes of Death
- (2011) Karin Helweg-Larsen SCANDINAVIAN JOURNAL OF PUBLIC HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started